A new CRISPR startup is betting regulators will ease up on gene-editing
Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU.
9 Jan 11:00 · MIT Technology Review
A new CRISPR startup is betting regulators will ease up on gene-editing
Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU.
9 Jan 11:00 · MIT Technology Review
last updated on 10 Jan 05:55